← Library
Not FDA approved and sold as a research chemical. This page is educational information only. It is not medical advice and not a recommendation to use anything.
IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Prostamax

Not FDA approved

Synthetic tetrapeptide bioregulator

Evidence score
21/ 100
Thin evidence

Very thin human evidence

  • Regulatory standing. Sold as a research chemical, not approved
  • Animal / preclinical only. Evidence is largely animal or in-vitro
  • No registered human trials. Nothing registered on ClinicalTrials.gov
  • 1 cited source. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Prostamax is a short synthetic peptide, reported as the tetrapeptide Lys-Glu-Asp-Pro, developed in Russia as one of the so-called Khavinson bioregulator peptides. It is described as being modeled on peptides from prostate tissue and is proposed to influence gene expression and chromatin in aging cells, though this mechanism is not well established.

What the evidence shows

Automatic summaryAnimal / preclinical

There are no registered human trials, and the roughly five published papers are mostly cell and animal studies from a small group of researchers. Any benefit for prostate health or aging in humans is unproven.

Key facts

Molecular formula
C20H33N5O9
Molecular weight
487.5 g/mol

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

0registered studies
Nonemost advanced phase
0completed (sample)
0recruiting (sample)

Published literature

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.